A carregar...

Sorafenib activity and disposition in liver cancer does not depend on organic cation transporter 1 (OCT1)

Systemic therapy of advanced hepatocellular carcinoma (HCC) with the small molecule multi-kinase inhibitor sorafenib is associated with large inter-individual pharmacokinetic variability and unpredictable side effects potentially requiring dose reduction or treatment termination. Organic cation tran...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Publicado no:Clin Pharmacol Ther
Main Authors: Chen, Mingqing, Neul, Claudia, Schaeffeler, Elke, Frisch, Franziska, Winter, Stefan, Schwab, Matthias, Koepsell, Hermann, Hu, Shuiying, Laufer, Stefan, Baker, Sharyn D., Sparreboom, Alex, Nies, Anne T.
Formato: Artigo
Idioma:Inglês
Publicado em: 2019
Assuntos:
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC6925656/
https://ncbi.nlm.nih.gov/pubmed/31350763
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1002/cpt.1588
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!